Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

308.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,067
Open 308.88
Bid (Size) 326.88 (1)
Ask (Size) 328.80 (17)
Prev. Close 308.88
Today's Range 308.88 - 308.88
52wk Range 188.53 - 319.74
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
A panel of experts will debate the merits of Biogen's drug, Leqembi. 
Via Investor's Business Daily

Performance

YTD
+13.30%
+13.30%
1 Month
-1.40%
-1.40%
3 Month
+20.39%
+20.39%
6 Month
+8.24%
+8.24%
1 Year
+52.74%
+52.74%

More News

Read More
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
Via Benzinga
Expert Ratings for Biogen
Via Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
Via Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Biogen Unusual Options Activity For May 26
Via Benzinga
Analyst Ratings for Biogen
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today
Via Benzinga
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
Via Investor's Business Daily
Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio
Via Benzinga
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
Via Investor's Business Daily
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Via Investor's Business Daily
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
Via Talk Markets
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Via InvestorPlace
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
Via The Motley Fool
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
Via MarketBeat
Exposures Product Safety
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.
Via Investor's Business Daily
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
Via The Motley Fool
3 Reasons to Buy Biogen Stock (and 1 to Sell)
Via The Motley Fool
Here’s What Eli Lilly’s Latest Clinical Win Means For Investors
Via The Motley Fool
Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.